Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Healthcare
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

FULC EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC

PR Newswire May 3, 2023

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors

Business Wire May 3, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile May 3, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fulcrum Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2023 - (NASDAQ: FULC)

PR Newswire May 3, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire May 3, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors

Business Wire May 2, 2023

INVESTOR ALERT: Berger Montague Advises Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire About a Securities Fraud Class Action Lawsuit by June 27, 2023

Newsfile May 2, 2023

FULC EQUITY ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FULC

Business Wire May 2, 2023

FULCRUM THERAPEUTICS, INC. (FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (FULC)

Newsfile May 2, 2023

Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of Class Action and to Actively Participate

PR Newswire May 2, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile May 2, 2023

FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)

PR Newswire May 2, 2023

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Fulcrum Therapeutics, Inc. (FULC) Investors

Business Wire May 1, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Business Wire May 1, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fulcrum Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FULC

Newsfile April 30, 2023

FULCRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire April 28, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Business Wire April 28, 2023

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Fulcrum Therapeutics, Inc. (FULC)

Business Wire April 28, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 7, 2023

Fulcrum Therapeutics Announces CFO Resignation

GlobeNewswire April 5, 2023